Special Issue

Extracellular Vesicles in Neurological Disorders: Translational Research

Message from the Guest Editors

In the last decade, extracellular vesicles (EVs) have attracted great interest as a mode of intercellular communication in numerous biological functions and pathological processes. EVs include exosomes and microvesicles that contain proteins, lipids, mRNAs, and miRNAs. EVs can even transmit key molecules to distant recipient cells through the blood–brain barrier (BBB). This ability to cross the BBB has inspired researchers to 1) design engineered vehicles that contained personalized cargo able to reach the central nervous system as a novel therapeutic approach for treating neurological diseases and 2) to identify biomarkers that provide real-time information about the damage and repair mechanisms involved in diseases.

In this Special Issue, we will summarize the implications of EVs in neurological disorders such as stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, migraine, and traumatic brain injury.

The topics of this Special Issue should be of interest not only for neurologists and neuroscientists but also for physicians in different areas of medicine.

Guest Editors

Dr. María Gutiérrez-Fernández

Neurological Sciences and Cerebrovascular Research Laboratory, Department of Neurology and Stroke Centre, Paseo Castellana 261, 28046 Madrid, Spain

Dr. Laura Otero-Ortega

Neurological Sciences and Cerebrovascular Research Laboratory, Department of Neurology and Stroke Centre, Neuroscience Area of IdiPAZ, Hospital La Paz Institute for Health Research–IdiPAZ, La Paz University Hospital, Universidad Autónoma de Madrid, Madrid 28046, Spain

Deadline for manuscript submissions

closed (31 August 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/87143

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).